Japan is the first to approve iPS drugs for the treatment of Parkinson's disease and heart failure
The Japanese Ministry of Health has given the green light for the commercial use of unique regenerative medicine products based on induced pluripotent stem cells (iPS). These drugs are intended for the treatment of severe forms of heart failure and Parkinson's disease, as reported by Kazinform citing SCMP. The approval concerns two drugs: ReHeart, which is used for the therapy of ischemic cardiomyopathy, and Amchepry, designed to correct degenerative changes caused by Parkinson's